NCT04281095View on ClinicalTrials.gov

A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Glabellar Frown Lines
Interventions
DRUG

Botulinum toxin type A

Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each

Trial Locations (1)

Unknown

Nowon Eulji Medical Center, Seoul

All Listed Sponsors
lead

ATGC Co., Ltd.

INDUSTRY

NCT04281095 - A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines | Biotech Hunter | Biotech Hunter